elevar
-
HLB Aims for Three Cancer Drug Approval and Groundbreaking Tumor-Agnostic Therapy by 2025Big Tech 2025. 2. 6. 16:38
· With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. SEOUL, South Korea, February 6, 2025 (IT Times) - With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. With just a mont..
-
HLB Announces Liver Cancer Treatment Results at ASCOBig Tech 2024. 6. 3. 16:47
· HLB's US subsidiary Elevar Therapeutics announced the updated Phase 3 CARES-310 study for uHCC at ASCO 2024. SEOUL, South Korea, June 3, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the updated Phase 3 CARES-310 study evaluating a novel combination therapy with rivoceranib in unresectable hepatocellular carcinoma (uHCC) was presented as a poster at the Ameri..